Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase 1/2 Multicenter, Open-Label, Dose-escalation and Expansion Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06260774
• Other study ID #: TTX-MC138-002
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: July 1, 2024
• Est. completion date: February 1, 2027

Study information

• Verified date: June 2024
• Source: TransCode Therapeutics
• Contact: Susan Duggan
• Phone: 8578373099
• Email: susan.duggan[@]transcodetherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors

Description:

The study will consist of 2 phases, dose escalation and dose expansion, with 3 study periods:

Screening (up to 28 days), Treatment (28-day treatment cycles, with dosing on Day 1), and Survival Follow-up (every 3 months). Each 28-day cycle is comprised of 1 dose of study drug administered as an intravenous (IV) infusion on Day 1.

A subject will continue on treatment until a dose limiting toxicity (DLT) is observed, other adverse event (AE) leading to unacceptable toxicity as assessed by the Investigator, progression of disease, or withdrawal of consent.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: February 1, 2027
• Est. primary completion date: February 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Have histologically or cytologically confirmed diagnosis of relapsed/refractory metastatic or locally advanced solid tumor where no standard therapy exists, standard therapy has failed and have no available therapies with known clinical benefit.

2. Must have measurable or evaluable disease per RECIST version 1.1.

3. =18 years at the time of informed consent.

4. Life expectancy of =3 months

5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2.

6. Have adequate organ function defined as:

1. Platelet count =75×109/L with no platelet transfusions in the past 7 days

2. Absolute neutrophil count =1.0×109/L

3. Hemoglobin =8 g/dL (red blood cell transfusion may be used to reach 8 g/dL but must have been administered at least 1 week prior to the administration of the study drug)

4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5× the upper limit of normal (ULN) if no hepatic metastases are present; <5× ULN if hepatic metastases are present

5. Total bilirubin <1.5× ULN; <3 X ULN in the presence of Gilbert's disease

6. Estimated (Cockcroft-Gault formula) or measured creatinine clearance =60 mL/min

7. International normalized ratio (INR) =1.5× ULN unless participant is receiving anticoagulant therapy as long as the prothrombin time (PT) or activated partial thromboplastin time (aPTT) is within therapeutic range of intended use of anticoagulants

7. If female of childbearing potential, either abstain from sexual intercourse or employ highly effective contraception measures during the study and for =30 days after the administration of the study drug. Highly effective measures include 2 forms of contraception. Postmenopausal or surgically sterile women (ie, hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) are eligible. Postmenopausal status is defined as either: amenorrheic for =12 months following cessation of exogenous hormonal treatments and without an alternative medical cause; luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for women <50 years of age; radiation-induced ovarian ablation with last menses =1 year ago; or chemotherapy-induced menopause with a =1-year interval since last menses. Female subjects must refrain from donating or banking eggs (ova, oocytes) and retrieving eggs for use during study treatment and for 30 days after the administration of the study drug.

8. For male subjects not surgically sterile, must either abstain from sexual intercourse or employ highly effective contraception (condoms or other barrier forms of contraception) during the study and for at least 30 days after the administration of the study drug. Male subjects should also avoid semen donation or providing semen for in vitro fertilization during the above-mentioned duration.

9. Able to understand and willing to provide informed consent and able to comply with the study procedures, including biopsy, and restrictions.

Exclusion Criteria:

1. Unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, or other study procedures and study restrictions.

2. Have received anticancer therapy (including both systemic therapy and radiotherapy, but not including immunotherapy or other antibody therapies) within 14 days or 5 half-lives (whichever is shorter) of study drug administration or;

a. received antibody therapy within 30 days before the start of study drug administration.

3. Have a history of a second primary malignancy that has been diagnosed or required active therapy within the past year.

a. Note: The following prior malignancies are not exclusionary: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate or breast cancer, curatively treated localized thyroid cancer, and completely resected carcinoma in situ of any site.

4. Have central nervous system (CNS) metastases or primary CNS tumor that is associated with progressive neurologic symptoms or requires ongoing corticosteroids to control the CNS disease. Subjects must have a stable neurologic status without steroid support for =2 weeks before the start of study drug administration. Subjects with stable or asymptomatic CNS metastases or primary CNS are eligible.

5. Require treatment with traditional/herbal medicines or their preparations indicated for tumors or with adjuvant anti-tumor effects that cannot be discontinued during the study.

6. Have clinically significant, uncontrolled cardiovascular disease including congestive heart failure Class III or Class IV according to the New York Heart Association classification; myocardial infarction or unstable angina within the previous 6 months; uncontrolled hypertension (Grade =3); or clinically significant, uncontrolled arrhythmia, including bradyarrhythmia that may cause QT prolongation (eg, Type II second-degree heart block or third-degree heart block).

7. Have QT interval corrected using Fridericia's formula >480 msec. Unless the subject has a history of prolonged QT syndrome or torsade de pointes or a familial history of prolonged QT syndrome.

8. Have a history of acute ischemic stroke, diagnosed by imaging (CT or MRI) or clinical diagnosis within 6 months prior to screening.

9. Have any severe or uncontrolled systemic disease or condition per clinical judgement, including: (i) uncontrolled hypertension or diabetes; (ii) serious cardiac, pulmonary, or renal conditions; (iii) active bleeding diatheses; (iv) any active type of bacterial, viral, fungal, or other infection that would pose a significant risk to the subject in the opinion of the Investigator; (v) cerebrovascular accident within the last 6 months before administration of study drug.

10. Have received a major surgical procedure within 28 days before the start of study drug administration (procedures such as central venous catheter placement and tumor needle biopsy are not considered major surgical procedures). The study center should discuss other minor surgeries with the sponsor.

11. Clinical diagnosis of hemochromatosis or secondary iron overload,

12. Have known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus infection that is not well-controlled and meets any of the following exclusion criteria:

1. Documented detectable HIV RNA within 4 weeks of study drug administration,

2. Acquired immunodeficiency syndrome defining opportunistic infections within the past 12 months prior to study enrollment, and

3. Is not on antiretroviral therapy for at least 4 weeks prior to study enrollment.

13. Have clinical signs or symptoms consistent with COVID-19 infection or confirmed infection by appropriate laboratory test (done at the discretion of Investigator or per local regulation) within the last 2 weeks before the administration of the study drug. In case of confirmed COVID-19 infection before screening, documentation of resolution of infection by appropriate laboratory test is required.

14. Have received or are planning to receive a COVID-19 vaccination within 2 weeks before or after the administration of the study drug. However, COVID-19 vaccinations received >2 weeks before or after the administration of the study drug are permitted.

15. Have received a live or live attenuated vaccines within 30 days before the administration of the study drug.

16. Have any unresolved clinically relevant toxicities from prior therapy, greater than NCI CTCAE Grade 1 at the time of starting study treatment, except for alopecia.

17. Have a history of hypersensitivity to active or inactive excipients of the study drug or drugs with a similar chemical structure or class to the study drug, including ferumoxytol (Feraheme®).

18. Have an active autoimmune disease (eg, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, ankylosing spondylitis, thyroiditis) requiring continuing immune suppressive therapy, including >10 mg prednisone per day or equivalent.

19. Pregnant or breastfeeding at the time of screening or on Day 1 before TTX-MC138 as documented by a serum beta human chorionic gonadotropin pregnancy test consistent with pregnancy.

20. Known current drug or alcohol abuse.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• TTX-MC138
The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.

Locations

Country	Name	City	State
United States	Mary Crowley Cancer Center	Dallas	Texas
United States	Next Oncology	Fairfax	Virginia
United States	MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
TransCode Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Escalation - Adverse Events	The safety and tolerability of escalating dose levels of TTX-MC138 to determine incidence of treatment-emergent adverse events (TEAEs).	Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year
Primary	Dose Escalation - Overall Response Rate (ORR)	proportion of subjects with a best response of CR, PR, or stable disease for at least 8 weeks per RECIST version 1.1.	Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year